Erasca, Inc. (ERAS) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $15.69, ERAS has negative trailing earnings (P/E not meaningful) and an ROE of -80.43%. Market capitalisation stands at $5.4B.
Balance sheet quality for ERAS: current ratio of 10.0, net cash position of $228.9M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $15.69 |
| Market Cap | $5.4B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 13.98 |
| EV / EBITDA | -19.85 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -80.43% |
| Return on Invested Capital | -37.52% |
| Return on Assets | -66.02% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.12 |
| Current Ratio | 8.29 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 5.45 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ERAS | Erasca, Inc. | $5.6B | 13.98 | -80.4% | |
| IOVA | Iovance Biotherapeutics, Inc. | $4.1B | 6.04 | -40.5% | |
| MBX | MBX Biosciences, Inc. Common Stock | $2.8B | 7.11 | -23.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
Price Performance
| 1 month | -13.35% |
| 3 months | +14.74% |
| Year-to-date | +321.62% |
| 1 year | +839.18% |
| 3 years | +542.80% |
52-Week Range
| 52-week High | $24.28 |
| 52-week Low | $1.65 |
| Avg Volume (90d) | 4.6M |
Related companies: ARVN · ATXS · AVBP · CRVS · CTMX · IOVA · MBX
Explore sector: Healthcare · Biotechnology
More sections of ERAS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks